# HIV Drug Access Crisis in Uganda

> Uganda's sex workers and HIV patients face shortages of promising lenacapavir shots despite FDA approval of affordable generic versions.
- Title: HIV Drug Access Crisis in Uganda · Seattletimes | Shortify
- Summary: Uganda's sex workers and HIV patients face shortages of promising lenacapavir shots despite FDA approval of affordable generic versions. Uganda's HIV…
- Keywords: lenacapavir, uganda, hiv, prep, gilead sciences, fda, mbarara, hiv prevention, news, local, Drug, Access
- Source: Seattletimes — https://seattletimes.com/business/promising-new-hiv-prevention-drug-is-hard-to-find-where-its-most-needed-in-places-like-uganda
- Read time: 1 min
- Topics: lenacapavir, uganda, hiv, prep, gilead sciences, fda, mbarara, hiv prevention, news, local
## Sex worker in Mbarara
Lisa Mutoni uses condoms to protect against HIV but faces condom removal during sex.

> They tell me that it is finished
## Lenacapavir promise
New drug lenacapavir offers near-complete hiv protection with two shots yearly.
## Access frustration
Sex workers and patients report lenacapavir shortages despite high demand.

> They tell me that it is finished
## FDA approval
U.s. food and drug administration tentatively approved lenacapavir generic version at $40 annual cost.
## Uganda's HIV rate
Mbarara city has 10% adult hiv rate double uganda's national average.
## Dose shortage
Only 40 lenacapavir doses received in april were used for pregnant mothers before expanding to others.
## Demand and supply gap
High demand for lenacapavir outpaces available doses in uganda's health centers.
## Key takeaway

Uganda's HIV prevention drug lenacapavir shortages persist despite FDA approving a $40 annual generic version for low-income countries.